Novadaq
Technologies Inc., trading under the ticker symbol NVDQ, was a medical
technology company that developed and marketed imaging solutions for
use in surgeries and diagnostic procedures. The company was
headquartered in Mississauga, Ontario, Canada.
Novadaq
Technologies was founded in 2000 and quickly established itself as a
leader in the field of fluorescence imaging. The company's products
and solutions included SPY Elite fluorescence imaging system, LUNA
fluorescence angiography system, and PINPOINT endoscopic fluorescence
imaging system, among others.
In 2017, Stryker Corporation
acquired Novadaq Technologies for approximately $701 million, and the
company was delisted from the Toronto Stock Exchange and NASDAQ stock
exchange.
Prior to its acquisition, as of its most recent
financial filings, Novadaq Technologies had revenues of approximately
$70 million and employed over 300 professionals across its various
operations worldwide. The company faced competition from other medical
technology companies operating in the imaging and surgical products
industries.
Investors who held NVDQ stock should have received
compensation from the acquisition. Investors who are interested in the
medical technology industry may want to research other publicly traded
companies in the sector, evaluate their financial performance,
competitive position, and growth
|
